Transfusion reaction and hemovigilance: An imperative discussion in Brazilian hemotherapy services

  • João Paulo dos Santos Rheumatology Division, Federal University of São Paulo - Escola Paulista de Medicina, São Paulo, SP, Brazil
  • Angela Alzamora
  • Mariana Dutra Teles
  • Veruska Lucena
  • Tatiana Almeida Omura de Paula
  • Talita Cardoso Gazzito Del Padre
  • Luiz Arthur Calheiros Leite
  • Horacio Rodrigues de Soares
  • Simone Lima Santos
  • Fernando Wagner da Silva Ramos


Transfusion of blood components is considered safer, but it took years to reach this level. One of the most effective ways to make blood transfusion a safer practice is hemovigilance, which provides important data, including the history of feared transfusion reactions. In recent years in Brazil, there has been an improvement in the reporting of transfusion reactions, however due to the great diversity of hematology services, there are still transfusion reactions. The aims of this study were described the main types of transfusion reactions, as well as to evaluate the underreporting importance of transfusion occurrences of hemotherapy services in Brazil.


1. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the transfusion of red blood cells. Blood Transfusion. 2009;7(1):49-64.
2. Li H, Zhao X, Li W, Zhao H. Claims and compensation for complications resulting from blood transfusions in China from 1998 to 2013. Transfusion and Apheresis Science.
3. Odaka C, Kato H, Otsubo H, Takamoto S, Okada Y, Taneichi M, et al. Online reporting system for transfusion-related adverse events to enhance recipient haemovigilance in Japan: A pilot study. Transfusion and Apheresis Science. 2013;48(1):95-102.
4. Refaai MA, Blumberg N. The transfusion dilemma – Weighing the known and newly proposed risks of blood transfusions against the uncertain benefits. Best Practice & Research Clinical Anaesthesiology. 2013;27(1):17-35.
5. Vincent JL. Which carries the biggest risk: Anaemia or blood transfusion? Transfusion Clinique et Biologique. 2015;22(3):148-50.
6. Saúde Md. Portaria nº 2712 - Redefine o Regulamento Técnico de Procediementos Hemoterápicos. 2013.
7. Anvisa ANdVS. Relatório de Hemovigilância Dados consolidados 2007- 2013. Brasília2014.
8. Bolton-Maggs PHB, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. British Journal of Haematology. 2013;163(3):303-14.
9. AuBuchon JP, Fung M, Whitaker B, Malasky J. AABB validation study of the CDC's National Healthcare Safety Network Hemovigilance Module adverse events definitions protocol. Transfusion. 2014;54(8):2077-83.
10. Carlier M, Vo Mai MP, Fauveau L, Ounnoughene N, Sandid I, Renaudier P. Dix-sept ans d’hémovigilance en France : bilan, perspectives. Transfusion Clinique et Biologique. 2011;18(2):140-50.
11. de Sousa Neto AL, Barbosa MH. Analysis of immediate transfusion incidents reported in a regional blood bank. Revista brasileira de hematologia e hemoterapia. 2011;33(5):337-41.
12. Folléa G, Aranko K. The revision of the European blood directives: A major challenge for transfusion medicine. Transfusion Clinique et Biologique. 2015;22(3):141-7.
13. Roback JD, Grossman BJ, Harris T, Hillyer CD. Technical Manual. In: AABB, editor. 17. Bethesda, Maryland2011.
14. Bordin JO, Langui Junior DM, Covas DT. Hemoterapia Fundamentos E Prática. In: Atheneu, editor.2007.
15. Heddle N, Webert KE. Chapter 50 - Febrile, Allergic, and Other Noninfectious Transfusion Reactions. In: Roback CDHESMNCAD, editor. Blood Banking and Transfusion Medicine (Second Edition). Philadelphia: Churchill Livingstone; 2007. p. 677-90.
16. Pruss A, Kalus U, Radtke H, Koscielny J, Baumann-Baretti B, Balzer D, et al. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions. Transfusion and Apheresis Science. 2004;30(1):41-6.
17. Tasaki T, Gotoh K, Fujii K, Sasaki S, Satoh S, Takadate J, et al. Accumulated cytokines in stored autologous blood do not cause febrile nonhemolytic transfusion reactions. Transfusion and Apheresis Science. 2008;39(1):15-9.
18. Tsantes AE, Kyriakou E, Nikolopoulos GK, Stylos D, Sidhom M, Bonovas S, et al. Cost-effectiveness of leucoreduction for prevention of febrile non-haemolytic transfusion reactions. Blood Transfusion. 2014;12(2):232-7.
19. Janatpour K, Holland PV. Noninfectious serious hazards of transfusion. Current hematology reports. 2002;1(2):149-55.
20. Hussain S, Moiz B, Ausat FA, Khurshid M. Monitoring and reporting transfusion reactions as a quality indicator – a clinical audit. Transfusion and Apheresis Science. 2015;52(1):122-7.
21. Harmening DM. Técnicas Modernas em Banco de Sangue e Transfusão. In: Revinter, editor. Rio de Janeiro2006.
22. Savage WJ, Hamilton RG, Tobian AAR, Milne GL, Kaufman RM, Savage JH, et al. Defining risk factors and presentations of allergic reactions to platelet transfusion. Journal of Allergy and Clinical Immunology. 2014;133(6):1772-5.e9.
23. Annen K, Olson JE. Optimizing platelet transfusions. Current opinion in hematology. 2015.
24. Knutson F, Osselaer J, Pierelli L, Lozano M, Cid J, Tardivel R, et al. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang. 2015.
25. Baltierra D, Harper T, Jones MP, Nau KC. Hematologic Disorders: Blood Transfusion Products. FP essentials. 2015;433:16-20.
26. Kaufman RM, Assmann SF, Triulzi DJ, Strauss RG, Ness P, Granger S, et al. Transfusion-related adverse events in the Platelet Dose study. Transfusion. 2015;55(1):144-53.
27. Oakley FD, Woods M, Arnold S, Young PP. Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products. Transfusion. 2015;55(3):563-70.
28. Sharma AD, Grocott HP. Platelet transfusion reactions: Febrile nonhemolytic reaction or bacterial contamination? Diagnosis, detection, and current preventive modalities. Journal of Cardiothoracic and Vascular Anesthesia. 2000;14(4):460-6.
29. Anvisa ANdVS. Manual Técnico De Hemovigilância - Investigação Das Reações Transfusionais Imediatas E Tardias Não Infecciosas. 2007.
30. Elhence P, Shenoy V, Verma A, Sachan D. Error reporting in transfusion medicine at a tertiary care centre: a patient safety initiative. Clin Chem Lab Med. 2012;50(11):1935-43.
31. Noizat-Pirenne F. Relevance of alloimmunization in haemolytic transfusion reaction in sickle cell disease. Transfus Clin Biol. 2012;19(3):132-8.
32. Sachan D, Jayakumar R, Varghese J, Rela M. An acute hemolytic transfusion reaction due to the "anti-c" rhesus antibody: A case report emphasizing the role of transfusion medicine. Asian journal of transfusion science. 2015;9(2):213-5.
33. Berseus O, Boman K, Nessen SC, Westerberg LA. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion. 2013;53 Suppl 1:114s-23s.
34. Alvarez P, Carrasco R, Romero-Dapueto C, Castillo RL. Transfusion-Related Acute Lung Injured (TRALI): Current Concepts. The open respiratory medicine journal. 2015;9:92-6.
35. Middelburg RA, van Stein D, Zupanska B, Uhrynowska M, Gajic O, Muñiz-Diaz E, et al. Female donors and transfusion-related acute lung injury: A case-referent study from the International TRALI Unisex Research Group. Transfusion. 2010;50(11):2447-54.
36. Serghini I, Nader Y, Qamouss Y, Zoubir M, Lalaoui JS, Boughalem M. [Trali or acute post-transfusion pulmonary edema: report of a case with review of the literature]. The Pan African medical journal. 2015;21:109.
37. Jutzi M, Levy G, Taleghani BM. Swiss Haemovigilance Data and Implementation of Measures for the Prevention of Transfusion Associated Acute Lung Injury (TRALI). Transfusion Medicine and Hemotherapy. 2008;35(2):98-101.
38. Benson AB, Moss M, Silliman CC. Transfusion-Related Acute Lung Injury (TRALI): A Clinical Review with Emphasis on the Critically Ill. British journal of haematology. 2009;147(4):431-43.
39. Dasararaju R, Marques MB. Adverse effects of transfusion. Cancer control : journal of the Moffitt Cancer Center. 2015;22(1):16-25.
40. Du Pont-Thibodeau G, Robitaille N, Gauvin F, Thibault L, Rivard GE, Lacroix J, et al. Incidence of hypotension and acute hypotensive transfusion reactions following platelet concentrate transfusions. Vox Sang. 2015.
41. Pagano MB, Ness PM, Chajewski OS, King KE, Wu Y, Tobian AA. Hypotensive transfusion reactions in the era of prestorage leukoreduction. Transfusion. 2015;55(7):1668-74.
42. Alam A, Lin Y, Lima A, Hansen M, Callum JL. The prevention of transfusion-associated circulatory overload. Transfus Med Rev. 2013;27(2):105-12.
43. Piccin A, Cronin M, Brady R, Sweeney J, Marcheselli L, Lawlor E. Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance Office 2000 to 2010. Transfusion. 2015;55(6):1223-30.
44. Anvisa ANdVS. Resolução Da Diretoria Colegiada – RDC N° 34 2014.
45. Kleinman S, Stassinopoulos A. Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion. 2015.
46. Kumar R, Gupta S, Kaur A, Gupta M. Individual donor-nucleic acid testing for human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safety. Asian journal of transfusion science. 2015;9(2):199-202.
47. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion. 2002;42(5):537-48.
48. Zhang JJ, Tian JJ, Wei SS, Duan SB, Wang HM, Chen YZ, et al. An Internal Reference Control Duplex Real-Time Polymerase Chain Reaction Assay for Detecting Bacterial Contamination in Blood Products. PLoS One. 2015;10(7):e0134743.
49. Naveen KN, Athanker SB, Rajoor U, Sindhoor J. Transfusion Associated Graft Versus Host Disease. Indian journal of dermatology. 2015;60(3):324.
50. Pagano MB, Tobian AAR. Complications of Transfusion. In: Mitchell LMMN, editor. Pathobiology of Human Disease. San Diego: Academic Press; 2014. p. 3182-93.
51. Pedrosa AKKV, Pinto FJM, Lins LDB, Deus GM. Blood transfusion reactions in children: Associated factors. Jornal de Pediatria (Versão em Português). 2013;89(4):400-6.
52. Ayob Y. Hemovigilance in developing countries. Biologicals. 2010;38(1):91-6.
53. Hannema SE, Brand A, van Meurs A, Smiers FJ. Delayed hemolytic transfusion reaction with hyperhemolysis after first red blood cell transfusion in child with beta-thalassemia: challenges in treatment. Transfusion. 2010;50(2):429-32.
54. Harvey AR, Basavaraju SV, Chung KW, Kuehnert MJ. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion. 2014.
55. Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015;169(5):746-53.
56. Williams Iii LA, Snyder EL. Transfusion-Related Adverse Events. Reference Module in Biomedical Sciences: Elsevier; 2014.
57. Hatano Y, Otsuka S, Chousa M, Saito S, Nollet KE, Ohto H, et al. Fatal delayed hemolytic transfusion reaction associated with anti-Dib and anti-E. Transfusion and Apheresis Science. 2012;47(3):263-8.
58. Osterman JL, Arora S. Blood Product Transfusions and Reactions. Emergency Medicine Clinics of North America. 2014;32(3):727-38.
59. Flood LS, Higbie J. A comparative assessment of nursing students' cognitive knowledge of blood transfusion using lecture and simulation. Nurse Education in Practice.
60. Jimenez-Marco T, Clemente-Marin G, Girona-Llobera E, Sedeño M, Muncunill J. A lesson to learn from Hemovigilance: The impact of nurses’ transfusion practice on mistransfusion. Transfusion and Apheresis Science.47(1):49-55.
How to Cite
SANTOS, João Paulo dos et al. Transfusion reaction and hemovigilance: An imperative discussion in Brazilian hemotherapy services. International Archives of Medicine, [S.l.], v. 10, oct. 2017. ISSN 1755-7682. Available at: <>. Date accessed: 13 nov. 2019. doi: